Multiple myeloma: open trials in Argentina

10 open trials have a site in Argentina. Registry data; only the trial team decides who can take part.

NCT07589634
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Hospital Alemán, Buenos Aires · Instituto Alexander Fleming, Buenos Aires · Hospital Italiano de Buenos Aires, Buenos Aires · Hospital Privado Centro Medico de Cordoba, Córdoba · Hospital Universitario Austral, Pilar
Registry updated 2026-11-03
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Buenos Aires · Buenos Aires · Chivilcoy · Córdoba · Rosario · S3000epv · Viedma
Registry updated 2026-10-30
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Hospital Italiano de Buenos Aires, ABB · ABB · Hospital Alemán, Buenos Aires
Registry updated 2026-10-29
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Hospital Privado Universitario de Córdoba, Córdoba · Sanatorio de la Mujer, Rosario
Registry updated 2026-10-27
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Hospital Italiano, Buenos Aires · Hospital Privado, Córdoba · Sanatorio Britanico Rosario, Rosario
Registry updated 2026-10-07
NCT05020236
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Trial Treatment · Phase 3 · Pfizer
FUNDALEU - Fundacion para combatir la Leucemia, Ciudad Autonoma de Buenos Aires · Alexander Fleming S.A (Instituto Medico Especializado Alexander Fleming), Ciudad Autonoma de Buenos Aires · FUNDALEU, Ciudad Autónoma de Buenos Aires · Hospital Italiano de La Plata, La Plata · Hospital Universitario Austral, Presidente Derqui · Sanatorio de la Mujer, Rosario
Registry updated 2026-08-24
NCT06152575
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Trial Treatment · Phase 3 · Pfizer
Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires · Hospital Italiano de Buenos Aires, Ciudad de Buenos Aires · Hospital Italiano de La Plata, La Plata · Hospital Universitario Austral, Pilar
Registry updated 2026-08-24
NCT05714839
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Trial Treatment · Phase 1/2 · GlaxoSmithKline
Capital Federal · Ciudadela · Rosario · San Juan Bautista · Viedma
Registry updated 2026-08-19
NCT06679101
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Trial Treatment · Phase 3 · GlaxoSmithKline
Capital Federal · Ciudad Autonoma de Buenos Aire · Córdoba · Rosario · Viedma
Registry updated 2026-04-22
NCT05879757
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Research · Takeda
Instituto Privado de Investigaciones Clinicas de Cordoba, Córdoba
Registry updated 2026-02-18

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error